$329 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 61 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | New | HORIZON THERAPEUTICS | $6,890,950 | – | 67,000 | +100.0% | 2.10% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES | $6,490,280 | – | 68,877 | +100.0% | 1.98% | – |
| MDGL | New | MADRIGAL PHARMS. | $4,227,300 | – | 18,300 | +100.0% | 1.29% | – |
| AXSM | New | AXSOME THERAPEUTICS | $4,185,940 | – | 58,300 | +100.0% | 1.27% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $3,662,297 | – | 78,489 | +100.0% | 1.12% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $2,152,976 | – | 18,800 | +100.0% | 0.66% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $1,630,075 | – | 48,099 | +100.0% | 0.50% | – |
| CYTK | New | CYTOKINETICS INC | $1,205,830 | – | 37,000 | +100.0% | 0.37% | – |
| New | MARINUS PHARMACEUTICALS INC | $977,400 | – | 90,000 | +100.0% | 0.30% | – | |
| SAGE | New | SAGE THERAPEUTICS INC | $939,400 | – | 20,000 | +100.0% | 0.29% | – |
| AGIO | New | AGIOS PHARMS. | $679,680 | – | 24,000 | +100.0% | 0.21% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $549,240 | – | 19,900 | +100.0% | 0.17% | – |
| New | AMYLYX PHARMACEUTICALS INC | $538,500 | – | 25,000 | +100.0% | 0.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.